1. Colony-Stimulating Factors

   • R. M. Fox

   OriginalPaper 17 November 2012 Pages: 1 - 8

2. Overview of the Lenograstim Pharmacoeconomics Programme

   • G. Oster
   • J. Menzin
   • V. Cour-Chabernaud

   OriginalPaper 17 November 2012 Pages: 9 - 17

3. Methodological Issues in Economic Assessments of New Therapies

   • M. Drummond
   • J. Menzin
   • G. Oster

   OriginalPaper 17 November 2012 Pages: 18 - 26

4. Economic Evaluation of Lenograstim (Glycosylated rHuG-CSF) in the Treatment of Inflammatory Breast Cancer for Germany and Italy

   • V. Mapelli
   • J. -M. Graf v.d. Schulenburg
   • F. Rossi

   OriginalPaper 17 November 2012 Pages: 27 - 35

5. Economic Analysis of Lenograstim in the Correction of Neutropenia Following Chemotherapy for Non-Hodgkin’s Lymphoma

   • Eric Souêtre
   • Wen Qing

   OriginalPaper 17 November 2012 Pages: 36 - 43

6. Economic Evaluation of Lenograstim for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer

   • Michael Drummond
   • Linda Davies

   OriginalPaper 17 November 2012 Pages: 44 - 52

7. Pharmacoeconomic Evaluation of Lenograstim

   • Joseph Menzin
   • Gerry Oster
   • Denise Richard

   OriginalPaper 17 November 2012 Pages: 53 - 60